메뉴 건너뛰기




Volumn 248, Issue 2, 2007, Pages 175-185

Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectives

Author keywords

Breast cancer; Primary chemotherapy; Primary endocrine therapy; Primary targeted therapy

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GEFITINIB; GEMCITABINE; LAPATINIB; LETROZOLE; NAVELBINE; PACLITAXEL; PREDNISOLONE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE;

EID: 33847255913     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.07.001     Document Type: Review
Times cited : (20)

References (87)
  • 1
    • 13744257860 scopus 로고    scopus 로고
    • Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis
    • Mauri D., Pavlidis N., and Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J. Natl. Cancer Inst. 97 (2005) 188-194
    • (2005) J. Natl. Cancer Inst. , vol.97 , pp. 188-194
    • Mauri, D.1    Pavlidis, N.2    Ioannidis, J.P.3
  • 2
    • 0024987463 scopus 로고
    • Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more
    • Bonadonna G., Veronesi U., Brambilla C., Ferrari L., Luini A., Greco M., et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J. Natl. Cancer Inst. 82 (1990) 1539-1545
    • (1990) J. Natl. Cancer Inst. , vol.82 , pp. 1539-1545
    • Bonadonna, G.1    Veronesi, U.2    Brambilla, C.3    Ferrari, L.4    Luini, A.5    Greco, M.6
  • 3
    • 17444454498 scopus 로고    scopus 로고
    • Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18
    • Fisher B., Brown A., Mamounas E., Wieand S., Robidoux A., Margolese R.G., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J. Clin. Oncol. 15 (1997) 2483-2493
    • (1997) J. Clin. Oncol. , vol.15 , pp. 2483-2493
    • Fisher, B.1    Brown, A.2    Mamounas, E.3    Wieand, S.4    Robidoux, A.5    Margolese, R.G.6
  • 4
    • 27944503994 scopus 로고    scopus 로고
    • High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer
    • Amat S., Abrial C., Penault-Llorca F., Delva R., Bougnoux P., Leduc B., et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast. Cancer Res. Treat. 94 (2005) 255-263
    • (2005) Breast. Cancer Res. Treat. , vol.94 , pp. 255-263
    • Amat, S.1    Abrial, C.2    Penault-Llorca, F.3    Delva, R.4    Bougnoux, P.5    Leduc, B.6
  • 5
    • 0035751675 scopus 로고    scopus 로고
    • Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18
    • Wolmark N., Wang J., Mamounas E., Bryant J., and Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl. Cancer Inst. Monogr. 30 (2001) 96-102
    • (2001) J. Natl. Cancer Inst. Monogr. , vol.30 , pp. 96-102
    • Wolmark, N.1    Wang, J.2    Mamounas, E.3    Bryant, J.4    Fisher, B.5
  • 6
    • 0033050164 scopus 로고    scopus 로고
    • Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
    • Kuerer H.M., Newman L.A., Smith T.L., Ames F.C., Hunt K.K., Dhingra K., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17 (1999) 460-469
    • (1999) J. Clin. Oncol. , vol.17 , pp. 460-469
    • Kuerer, H.M.1    Newman, L.A.2    Smith, T.L.3    Ames, F.C.4    Hunt, K.K.5    Dhingra, K.6
  • 7
    • 0031926839 scopus 로고    scopus 로고
    • Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
    • Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E.R., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16 (1998) 2672-2685
    • (1998) J. Clin. Oncol. , vol.16 , pp. 2672-2685
    • Fisher, B.1    Bryant, J.2    Wolmark, N.3    Mamounas, E.4    Brown, A.5    Fisher, E.R.6
  • 8
    • 0036498789 scopus 로고    scopus 로고
    • Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes
    • Rouzier R., Extra J.M., Klijanienko J., Falcou M.C., Asselain B., Vincent-Salomon A., et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J. Clin. Oncol. 20 (2002) 1304-1310
    • (2002) J. Clin. Oncol. , vol.20 , pp. 1304-1310
    • Rouzier, R.1    Extra, J.M.2    Klijanienko, J.3    Falcou, M.C.4    Asselain, B.5    Vincent-Salomon, A.6
  • 9
    • 33644529487 scopus 로고    scopus 로고
    • Outcome after pathologic complete eradication of cytologically proven breast,cancer axillary node metastases following primary chemotherapy
    • Hennessy B.T., Hortobagyi G.N., Rouzier R., Kuerer H., Sneige N., Buzdar A.U., et al. Outcome after pathologic complete eradication of cytologically proven breast,cancer axillary node metastases following primary chemotherapy. J. Clin. Oncol. 23 (2005) 9304-9311
    • (2005) J. Clin. Oncol. , vol.23 , pp. 9304-9311
    • Hennessy, B.T.1    Hortobagyi, G.N.2    Rouzier, R.3    Kuerer, H.4    Sneige, N.5    Buzdar, A.U.6
  • 10
    • 33646375742 scopus 로고    scopus 로고
    • Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
    • Kaufmann M., Hortobagyi G.N., Goldhirsch A., Scholl S., Makris A., Valagussa P., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J. Clin. Oncol. 24 (2006) 1940-1949
    • (2006) J. Clin. Oncol. , vol.24 , pp. 1940-1949
    • Kaufmann, M.1    Hortobagyi, G.N.2    Goldhirsch, A.3    Scholl, S.4    Makris, A.5    Valagussa, P.6
  • 11
    • 33644546434 scopus 로고    scopus 로고
    • Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer
    • Kuroi K., Toi M., Tsuda H., Kurosumi M., and Akiyama F. Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. Biomed. Pharmacother. 59 (2005) s387-s392
    • (2005) Biomed. Pharmacother. , vol.59
    • Kuroi, K.1    Toi, M.2    Tsuda, H.3    Kurosumi, M.4    Akiyama, F.5
  • 12
    • 33646445341 scopus 로고    scopus 로고
    • Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel project protocol B-27
    • Bear H.D., Anderson S., Smith R.E., Geyer Jr. C.E., Mamounas E.P., Fisher B., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel project protocol B-27. J. Clin. Oncol. 24 (2006) 2019-2027
    • (2006) J. Clin. Oncol. , vol.24 , pp. 2019-2027
    • Bear, H.D.1    Anderson, S.2    Smith, R.E.3    Geyer Jr., C.E.4    Mamounas, E.P.5    Fisher, B.6
  • 13
    • 5144219905 scopus 로고    scopus 로고
    • Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment
    • Colleoni M., Viale G., Zahrieh D., Pruneri G., Gentilini O., Veronesi P., et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin. Cancer Res. 10 (2004) 6622-6628
    • (2004) Clin. Cancer Res. , vol.10 , pp. 6622-6628
    • Colleoni, M.1    Viale, G.2    Zahrieh, D.3    Pruneri, G.4    Gentilini, O.5    Veronesi, P.6
  • 14
    • 0037103104 scopus 로고    scopus 로고
    • Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18
    • Fisher E.R., Wang J., Bryant J., Fisher B., Mamounas E., and Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95 (2002) 681-695
    • (2002) Cancer , vol.95 , pp. 681-695
    • Fisher, E.R.1    Wang, J.2    Bryant, J.3    Fisher, B.4    Mamounas, E.5    Wolmark, N.6
  • 16
    • 33644973070 scopus 로고    scopus 로고
    • Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
    • Guarneri V., Broglio K., Kau S.W., Cristofanilli M., Buzdar A.U., Valero V., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J. Clin. Oncol. 24 (2006) 1037-1044
    • (2006) J. Clin. Oncol. , vol.24 , pp. 1037-1044
    • Guarneri, V.1    Broglio, K.2    Kau, S.W.3    Cristofanilli, M.4    Buzdar, A.U.5    Valero, V.6
  • 17
    • 2642585065 scopus 로고    scopus 로고
    • A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial
    • Smith I.E., A'Hern R.P., Coombes G.A., Howell A., Ebbs S.R., Hickish T.F., et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann. Oncol. 15 (2004) 751-758
    • (2004) Ann. Oncol. , vol.15 , pp. 751-758
    • Smith, I.E.1    A'Hern, R.P.2    Coombes, G.A.3    Howell, A.4    Ebbs, S.R.5    Hickish, T.F.6
  • 18
    • 24044515003 scopus 로고    scopus 로고
    • Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomized phase III trial (TOPIC 2)
    • Chua S., Smith I.E., A'Hern R.P., Coombes G.A., Hickish T.F., Robinson A.C., et al. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomized phase III trial (TOPIC 2). Ann. Oncol. 16 (2005) 1435-1441
    • (2005) Ann. Oncol. , vol.16 , pp. 1435-1441
    • Chua, S.1    Smith, I.E.2    A'Hern, R.P.3    Coombes, G.A.4    Hickish, T.F.5    Robinson, A.C.6
  • 19
    • 4243252937 scopus 로고    scopus 로고
    • Intensified anthracyclin doses do not improve clinical and pathological responses to neoadjuvant FEC for operable breast cancer (BC): results of a multicenter randomized trial
    • abs 254
    • Pelissier P., Delaloge S., Mathieu M.C., Jeanblanc G., Petit T., Eymard J.C., et al. Intensified anthracyclin doses do not improve clinical and pathological responses to neoadjuvant FEC for operable breast cancer (BC): results of a multicenter randomized trial. Proc. Am. Soc. Clin. Oncol. (2002) abs 254
    • (2002) Proc. Am. Soc. Clin. Oncol.
    • Pelissier, P.1    Delaloge, S.2    Mathieu, M.C.3    Jeanblanc, G.4    Petit, T.5    Eymard, J.C.6
  • 20
    • 0035253733 scopus 로고    scopus 로고
    • French Adjuvant Study Group, Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial, J. Clin. Oncol. 19 (3) (2001) 602-611.
  • 21
    • 0032751112 scopus 로고    scopus 로고
    • Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer
    • Buzdar A.U., Singletary S.E., Theriault R.L., Booser D.J., Valero V., Ibrahim N.L., et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J. Clin. Oncol. 17 (1999) 3412-3417
    • (1999) J. Clin. Oncol. , vol.17 , pp. 3412-3417
    • Buzdar, A.U.1    Singletary, S.E.2    Theriault, R.L.3    Booser, D.J.4    Valero, V.5    Ibrahim, N.L.6
  • 22
    • 7044249032 scopus 로고    scopus 로고
    • Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study
    • Schneeweiss A., Huober J., Sinn H.P., von Fournier D., Rudlowski C., Beldermann F., et al. Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. Eur. J. Cancer 40 (2004) 2432-2438
    • (2004) Eur. J. Cancer , vol.40 , pp. 2432-2438
    • Schneeweiss, A.1    Huober, J.2    Sinn, H.P.3    von Fournier, D.4    Rudlowski, C.5    Beldermann, F.6
  • 23
    • 24944535396 scopus 로고    scopus 로고
    • Primary chemotherapy with Gemcitabine, Epirubicin and Taxol (GET) in operable breast cancer: a phase II study
    • Conte P.F., Donati S., Gennari A., Guarneri V., Orlandini C., Rondini M., et al. Primary chemotherapy with Gemcitabine, Epirubicin and Taxol (GET) in operable breast cancer: a phase II study. Brit. J. Cancer 93 (2005) 406-411
    • (2005) Brit. J. Cancer , vol.93 , pp. 406-411
    • Conte, P.F.1    Donati, S.2    Gennari, A.3    Guarneri, V.4    Orlandini, C.5    Rondini, M.6
  • 24
    • 0037083497 scopus 로고    scopus 로고
    • Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study
    • de Matteis A., Nuzzo F., D'Aiuto G., Labonia V., Landi G., Rossi E., et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer 94 (2002) 895-901
    • (2002) Cancer , vol.94 , pp. 895-901
    • de Matteis, A.1    Nuzzo, F.2    D'Aiuto, G.3    Labonia, V.4    Landi, G.5    Rossi, E.6
  • 25
    • 12144262655 scopus 로고    scopus 로고
    • Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer
    • Malhotra V., Dorr V.J., Lyss A.P., Anderson C.M., Westgate S., Reynolds M., et al. Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. Clin. Breast Cancer 5 (2004) 377-384
    • (2004) Clin. Breast Cancer , vol.5 , pp. 377-384
    • Malhotra, V.1    Dorr, V.J.2    Lyss, A.P.3    Anderson, C.M.4    Westgate, S.5    Reynolds, M.6
  • 26
    • 19944424117 scopus 로고    scopus 로고
    • Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer
    • Espinosa E., Morales S., Borrega P., Casas A., Madronal C., Machengs I., et al. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemoth. Pharm. 54 (2004) 546-552
    • (2004) Cancer Chemoth. Pharm. , vol.54 , pp. 546-552
    • Espinosa, E.1    Morales, S.2    Borrega, P.3    Casas, A.4    Madronal, C.5    Machengs, I.6
  • 27
    • 0036177015 scopus 로고    scopus 로고
    • Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel + granulocyte colony stimulating factor
    • Wenzel C., Locker G.J., Schmidinger M., Rudas M., Taucher S., Gnant M.F., et al. Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel + granulocyte colony stimulating factor. Anticancer Drugs 13 (2002) 67-74
    • (2002) Anticancer Drugs , vol.13 , pp. 67-74
    • Wenzel, C.1    Locker, G.J.2    Schmidinger, M.3    Rudas, M.4    Taucher, S.5    Gnant, M.F.6
  • 28
    • 10744227179 scopus 로고    scopus 로고
    • Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer
    • Ganem G., Tubiana-Hulin M., Fumoleau P., Combe M., Misset J.L., Vannetzel J.M., et al. Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann. Oncol. 14 (2003) 1623-1628
    • (2003) Ann. Oncol. , vol.14 , pp. 1623-1628
    • Ganem, G.1    Tubiana-Hulin, M.2    Fumoleau, P.3    Combe, M.4    Misset, J.L.5    Vannetzel, J.M.6
  • 29
    • 0036860308 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group
    • Gogas H., Papadimitriou C., Kalofonos H.P., Bafaloukos D., Fountzilas G., Tsavdaridis D., et al. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann. Oncol. 13 (2002) 1737-1742
    • (2002) Ann. Oncol. , vol.13 , pp. 1737-1742
    • Gogas, H.1    Papadimitriou, C.2    Kalofonos, H.P.3    Bafaloukos, D.4    Fountzilas, G.5    Tsavdaridis, D.6
  • 30
    • 17944384873 scopus 로고    scopus 로고
    • Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer
    • Moliterni A., Tarenzi E., Capri G., Terenziani M., Bertuzzi A., Grasselli G., et al. Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Semin. Oncol. S17 (1997) 10-14
    • (1997) Semin. Oncol. , vol.S17 , pp. 10-14
    • Moliterni, A.1    Tarenzi, E.2    Capri, G.3    Terenziani, M.4    Bertuzzi, A.5    Grasselli, G.6
  • 31
    • 0034493019 scopus 로고    scopus 로고
    • Epidoxorubicin and paclitaxel as primary chemotherapy for T > 3 cm and T4 breast cancer patients
    • Bellino R., Cortese P., Danese S., De Sanctis C., Durando A., Genta F., Grio R., et al. Epidoxorubicin and paclitaxel as primary chemotherapy for T > 3 cm and T4 breast cancer patients. Anticancer Res. 29 (2000) 4825-4828
    • (2000) Anticancer Res. , vol.29 , pp. 4825-4828
    • Bellino, R.1    Cortese, P.2    Danese, S.3    De Sanctis, C.4    Durando, A.5    Genta, F.6    Grio, R.7
  • 32
    • 23544439804 scopus 로고    scopus 로고
    • Breast conserving surgery after neoadjuvant chemotherapy paclitaxel + doxorubicin vs fluorouracil + doxorubicin + cyclophosphamide
    • (abstr 159)
    • Semiglazov V.F., Bojok A.A., Arsumanov A.S., Ivanova O.A., Ivanov V.G., Semiglazov V.V., et al. Breast conserving surgery after neoadjuvant chemotherapy paclitaxel + doxorubicin vs fluorouracil + doxorubicin + cyclophosphamide. Breast Cancer Res. Treat. 7 (2002) S:52 (abstr 159)
    • (2002) Breast Cancer Res. Treat. , vol.7
    • Semiglazov, V.F.1    Bojok, A.A.2    Arsumanov, A.S.3    Ivanova, O.A.4    Ivanov, V.G.5    Semiglazov, V.V.6
  • 33
    • 21144439271 scopus 로고    scopus 로고
    • Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study
    • Evans T.R., Yellowlees A., Foster E., Earl H., Cameron D.A., Hutcheon A.W., et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study. J. Clin. Oncol. 23 (2005) 2988-2995
    • (2005) J. Clin. Oncol. , vol.23 , pp. 2988-2995
    • Evans, T.R.1    Yellowlees, A.2    Foster, E.3    Earl, H.4    Cameron, D.A.5    Hutcheon, A.W.6
  • 34
    • 16644384267 scopus 로고    scopus 로고
    • Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer
    • Dieras V., Fumoleau P., Romieu G., Tubiana-Hulin M., Namer M., Mauriac L., et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J. Clin. Oncol. 22 (2004) 4958-4965
    • (2004) J. Clin. Oncol. , vol.22 , pp. 4958-4965
    • Dieras, V.1    Fumoleau, P.2    Romieu, G.3    Tubiana-Hulin, M.4    Namer, M.5    Mauriac, L.6
  • 36
    • 24044545225 scopus 로고    scopus 로고
    • Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer
    • Reitsamer R., Peintinger F., Prokop E., and Hitzl W. Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anticancer Drugs 168 (2005) 867-870
    • (2005) Anticancer Drugs , vol.168 , pp. 867-870
    • Reitsamer, R.1    Peintinger, F.2    Prokop, E.3    Hitzl, W.4
  • 37
    • 4444305144 scopus 로고    scopus 로고
    • A multicenter randomized phase II study of 4 or 6 cycles of adriamycin/taxol (paclitaxel) (AT) as neoadjuvant treatment of breast cancer (BC)
    • (abs 118)
    • Roumieu G., Tubiana-Hulin M., Fumoleau P., Namer M., Delva R., Guastalla J.P., et al. A multicenter randomized phase II study of 4 or 6 cycles of adriamycin/taxol (paclitaxel) (AT) as neoadjuvant treatment of breast cancer (BC). Ann. Oncol. 13 (2002) (abs 118)
    • (2002) Ann. Oncol. , vol.13
    • Roumieu, G.1    Tubiana-Hulin, M.2    Fumoleau, P.3    Namer, M.4    Delva, R.5    Guastalla, J.P.6
  • 38
    • 29344467956 scopus 로고    scopus 로고
    • Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouraciland its effects on tumor response as preoperative therapy
    • Gianni L., Baselga J., Eiermann W., Guillem Porta V., Semiglazov V., Lluch A., et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouraciland its effects on tumor response as preoperative therapy. Clin. Cancer Res. 11 (2005) 8715-8721
    • (2005) Clin. Cancer Res. , vol.11 , pp. 8715-8721
    • Gianni, L.1    Baselga, J.2    Eiermann, W.3    Guillem Porta, V.4    Semiglazov, V.5    Lluch, A.6
  • 39
    • 0037087562 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel
    • Smith I.C., Heys S.D., Hutcheon A.W., Miller I.D., Payne S., Gilbert F.J., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J. Clin. Oncol. 20 (2002) 1456-1466
    • (2002) J. Clin. Oncol. , vol.20 , pp. 1456-1466
    • Smith, I.C.1    Heys, S.D.2    Hutcheon, A.W.3    Miller, I.D.4    Payne, S.5    Gilbert, F.J.6
  • 41
    • 19944426993 scopus 로고    scopus 로고
    • In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study
    • von Minckwitz G., Blohmer J.U., Raab G., Lohr A., Gerber B., Heinrich G., et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann. Oncol. 16 (2005) 56-63
    • (2005) Ann. Oncol. , vol.16 , pp. 56-63
    • von Minckwitz, G.1    Blohmer, J.U.2    Raab, G.3    Lohr, A.4    Gerber, B.5    Heinrich, G.6
  • 42
    • 0035425528 scopus 로고    scopus 로고
    • Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study
    • von Minckwitz G., Costa S.D., Raab G., Blohmer J.U., Eidtmann H., Hilfrich J., et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J. Clin. Oncol. 19 (2001) 3506-3515
    • (2001) J. Clin. Oncol. , vol.19 , pp. 3506-3515
    • von Minckwitz, G.1    Costa, S.D.2    Raab, G.3    Blohmer, J.U.4    Eidtmann, H.5    Hilfrich, J.6
  • 43
    • 24944542869 scopus 로고    scopus 로고
    • Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
    • Green M.C., Buzdar A.U., Smith T., Ibrahim N.K., Valero V., Rosales M.F., et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J. Clin. Oncol. 23 (2005) 5983-5992
    • (2005) J. Clin. Oncol. , vol.23 , pp. 5983-5992
    • Green, M.C.1    Buzdar, A.U.2    Smith, T.3    Ibrahim, N.K.4    Valero, V.5    Rosales, M.F.6
  • 44
    • 0242418151 scopus 로고    scopus 로고
    • Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer
    • Baldini E., Gardin G., Giannessi P.G., et al. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann. Oncol. 14 (2003) 227-232
    • (2003) Ann. Oncol. , vol.14 , pp. 227-232
    • Baldini, E.1    Gardin, G.2    Giannessi, P.G.3
  • 45
    • 4143106340 scopus 로고    scopus 로고
    • Dose and time intensified epirubicin/cyclophosphamide (EC) in locally advanced breast cancer
    • (abs 154)
    • Euler U., Dresel V., Bühner M., Volkholz H., and Tulusan A.H.T. Dose and time intensified epirubicin/cyclophosphamide (EC) in locally advanced breast cancer. Breast Cancer Res. Treat. 76 (2002) (abs 154)
    • (2002) Breast Cancer Res. Treat. , vol.76
    • Euler, U.1    Dresel, V.2    Bühner, M.3    Volkholz, H.4    Tulusan, A.H.T.5
  • 46
    • 0032885642 scopus 로고    scopus 로고
    • Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group
    • Miller K.D., McCaskill-Stevens W., Sisk J., Loesch D.M., Monaco F., Seshadri R., et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J. Clin. Oncol. 17 (1999) 3033-3037
    • (1999) J. Clin. Oncol. , vol.17 , pp. 3033-3037
    • Miller, K.D.1    McCaskill-Stevens, W.2    Sisk, J.3    Loesch, D.M.4    Monaco, F.5    Seshadri, R.6
  • 47
    • 0033060223 scopus 로고    scopus 로고
    • Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel
    • von Minckwitz G., Costa S.D., Eiermann W., Blohmer J.U., Tulusan A.H., Jackisch C., et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J. Clin. Oncol. 17 (1999) 1999-2005
    • (1999) J. Clin. Oncol. , vol.17 , pp. 1999-2005
    • von Minckwitz, G.1    Costa, S.D.2    Eiermann, W.3    Blohmer, J.U.4    Tulusan, A.H.5    Jackisch, C.6
  • 48
    • 33750710254 scopus 로고    scopus 로고
    • Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer
    • Epub ahead of print
    • Cooper B.W., Radivoyevitch T., Overmoyer B.A., Shenk R.R., Pham H.T., Samuels J.R., et al. Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer. Breast Cancer Res. Treat. (2005) 1-8 Epub ahead of print
    • (2005) Breast Cancer Res. Treat. , pp. 1-8
    • Cooper, B.W.1    Radivoyevitch, T.2    Overmoyer, B.A.3    Shenk, R.R.4    Pham, H.T.5    Samuels, J.R.6
  • 49
    • 0038561594 scopus 로고    scopus 로고
    • Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study
    • abs 133
    • Untch M., Konency G., Ditsch N., et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study. Proc. Am. Soc. Clin. Oncol. 21 (2002) 34a abs 133
    • (2002) Proc. Am. Soc. Clin. Oncol. , vol.21
    • Untch, M.1    Konency, G.2    Ditsch, N.3
  • 50
    • 21044454272 scopus 로고    scopus 로고
    • Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group
    • von Minckwitz G., Raab G., Caputo A., Schutte M., Hilfrich J., Blohmer J.U., et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J. Clin. Oncol. 23 (2005) 2676-2685
    • (2005) J. Clin. Oncol. , vol.23 , pp. 2676-2685
    • von Minckwitz, G.1    Raab, G.2    Caputo, A.3    Schutte, M.4    Hilfrich, J.5    Blohmer, J.U.6
  • 51
    • 0020061006 scopus 로고
    • Tamoxifen as initial sole treatment of localized breast cancer in elderly women: a pilot study
    • Preece P.E., Wood R.A.B., Mackie C.R., and Cuschieri A. Tamoxifen as initial sole treatment of localized breast cancer in elderly women: a pilot study. Br. Med. J. 284 (1982) 869-870
    • (1982) Br. Med. J. , vol.284 , pp. 869-870
    • Preece, P.E.1    Wood, R.A.B.2    Mackie, C.R.3    Cuschieri, A.4
  • 52
    • 0028910481 scopus 로고
    • Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease
    • Bergman L., van Dongen J.A., van Ooijen B., and van Leeuwen F.E. Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease. Breast Cancer Res. Treat. 34 (1995) 77-83
    • (1995) Breast Cancer Res. Treat. , vol.34 , pp. 77-83
    • Bergman, L.1    van Dongen, J.A.2    van Ooijen, B.3    van Leeuwen, F.E.4
  • 53
    • 0031006008 scopus 로고    scopus 로고
    • Investigation of primary tamoxifen therapy for elderly patients with operable breast cancer
    • Willsher P.C., Robertson J.F.R., Jackson L., Al-Hilaly M., and Blarney R.W. Investigation of primary tamoxifen therapy for elderly patients with operable breast cancer. Breast 6 (1997) 150-154
    • (1997) Breast , vol.6 , pp. 150-154
    • Willsher, P.C.1    Robertson, J.F.R.2    Jackson, L.3    Al-Hilaly, M.4    Blarney, R.W.5
  • 54
    • 12244294506 scopus 로고    scopus 로고
    • Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial
    • Mustacchi G., Ceccherini R., Milani S., Pluchinotta A., De Matteis A., Maiorino L., et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann. Oncol. 14 (2003) 414-420
    • (2003) Ann. Oncol. , vol.14 , pp. 414-420
    • Mustacchi, G.1    Ceccherini, R.2    Milani, S.3    Pluchinotta, A.4    De Matteis, A.5    Maiorino, L.6
  • 55
    • 0142181118 scopus 로고    scopus 로고
    • ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98 2003 1802-1810.
  • 57
    • 10744223655 scopus 로고    scopus 로고
    • A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
    • Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350 (2004)
    • (2004) N. Engl. J. Med. , vol.350
    • Coombes, R.C.1    Hall, E.2    Gibson, L.J.3    Paridaens, R.4    Jassem, J.5    Delozier, T.6
  • 58
    • 3142737587 scopus 로고    scopus 로고
    • Primary hormonal therapy with exemestane in patients with breast tumors >3 cm in diameter: results of a Spanish multicenter phase II trial
    • (abs 603)
    • Gil M.J., Barnadas A., Cirera L., Tusquets I., Muñoz M., Arcusa A., et al. Primary hormonal therapy with exemestane in patients with breast tumors >3 cm in diameter: results of a Spanish multicenter phase II trial. Proc. Am. Soc. Clin. Oncol. 23 (2004) (abs 603)
    • (2004) Proc. Am. Soc. Clin. Oncol. , vol.23
    • Gil, M.J.1    Barnadas, A.2    Cirera, L.3    Tusquets, I.4    Muñoz, M.5    Arcusa, A.6
  • 59
    • 0035692576 scopus 로고    scopus 로고
    • Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study
    • Eiermann W., Paepke S., Appfelstaedt J., Llombart-Cussac A., Eremin J., Vinholes J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol. 12 (2001) 1527-1532
    • (2001) Ann. Oncol. , vol.12 , pp. 1527-1532
    • Eiermann, W.1    Paepke, S.2    Appfelstaedt, J.3    Llombart-Cussac, A.4    Eremin, J.5    Vinholes, J.6
  • 60
    • 0035884620 scopus 로고    scopus 로고
    • Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial
    • Ellis M.J., Coop A., Singh B., Mauriac L., Llombert-Cussac A., Janicke F., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 19 (2001) 3808-3816
    • (2001) J. Clin. Oncol. , vol.19 , pp. 3808-3816
    • Ellis, M.J.1    Coop, A.2    Singh, B.3    Mauriac, L.4    Llombert-Cussac, A.5    Janicke, F.6
  • 61
    • 10744233578 scopus 로고    scopus 로고
    • Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status
    • Ellis M.J., Coop A., Singh B., Tao Y., Llombart-Cussac A., Janicke F., et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 63 (2003) 6523-6531
    • (2003) Cancer Res. , vol.63 , pp. 6523-6531
    • Ellis, M.J.1    Coop, A.2    Singh, B.3    Tao, Y.4    Llombart-Cussac, A.5    Janicke, F.6
  • 62
    • 24644490871 scopus 로고    scopus 로고
    • Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
    • Smith I.E., Dowsett M., Ebbs S.R., Dixon M., Skene A., Blohmer J.U., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. 23 (2005) 5108-5116
    • (2005) J. Clin. Oncol. , vol.23 , pp. 5108-5116
    • Smith, I.E.1    Dowsett, M.2    Ebbs, S.R.3    Dixon, M.4    Skene, A.5    Blohmer, J.U.6
  • 63
    • 20244374413 scopus 로고    scopus 로고
    • Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer - a Study from the IMPACT Trialists
    • Dowsett M., Ebbs S.R., Dixon J.M., Skene A., Griffith C., Boeddinghaus I., et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer - a Study from the IMPACT Trialists. J. Clin. Oncol. 23 (2005) 2477-2492
    • (2005) J. Clin. Oncol. , vol.23 , pp. 2477-2492
    • Dowsett, M.1    Ebbs, S.R.2    Dixon, J.M.3    Skene, A.4    Griffith, C.5    Boeddinghaus, I.6
  • 64
    • 33749522748 scopus 로고    scopus 로고
    • On behalf of the IMPACT Trialists, Ki-67 after 2 weeks' endocrine treatment predicts relapse-free survival (RFS) in the IMPACT trial
    • (abs 45)
    • Dowsett M., A'Hern R., and Smith I. On behalf of the IMPACT Trialists, Ki-67 after 2 weeks' endocrine treatment predicts relapse-free survival (RFS) in the IMPACT trial. Breast Cancer Res. Treat. (2005) (abs 45)
    • (2005) Breast Cancer Res. Treat.
    • Dowsett, M.1    A'Hern, R.2    Smith, I.3
  • 66
    • 12144262989 scopus 로고    scopus 로고
    • Multi-center study of pre-operative treatment with Letrozole for optimal duration of treatment in postmenopausal women with ER and/or PGR positive breast cancer
    • (abs 321)
    • Paepke S., Tulusan A., Kiesel L., Bastert G., Jaenicke F.K., Bouterfa H., et al. Multi-center study of pre-operative treatment with Letrozole for optimal duration of treatment in postmenopausal women with ER and/or PGR positive breast cancer. Proc. Am. Soc. Clin. Oncol. 22 (2003) (abs 321)
    • (2003) Proc. Am. Soc. Clin. Oncol. , vol.22
    • Paepke, S.1    Tulusan, A.2    Kiesel, L.3    Bastert, G.4    Jaenicke, F.K.5    Bouterfa, H.6
  • 67
    • 18744395754 scopus 로고    scopus 로고
    • Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing Stage II or III breast cancer: a pilot study
    • Burstein H.J., Harris L.N., Gelman R., Lester S.C., Nunes R.A., Kaelin C.M., et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing Stage II or III breast cancer: a pilot study. J. Clin. Oncol. 21 (2003) 46-53
    • (2003) J. Clin. Oncol. , vol.21 , pp. 46-53
    • Burstein, H.J.1    Harris, L.N.2    Gelman, R.3    Lester, S.C.4    Nunes, R.A.5    Kaelin, C.M.6
  • 68
    • 33646376727 scopus 로고    scopus 로고
    • Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer
    • Hurley J., Doliny P., Reis I., Silva O., Gomez-Fernandez C., Velez P., et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J. Clin. Oncol. 24 (2006) 1831-1838
    • (2006) J. Clin. Oncol. , vol.24 , pp. 1831-1838
    • Hurley, J.1    Doliny, P.2    Reis, I.3    Silva, O.4    Gomez-Fernandez, C.5    Velez, P.6
  • 69
    • 3843106892 scopus 로고    scopus 로고
    • Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study
    • Wenzel C., Hussian D., Bartsch R., Pluschnig U., Locker G.J., Rudas M., et al. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J. Cancer Res. Clin. Oncol. 130 (2004) 400-404
    • (2004) J. Cancer Res. Clin. Oncol. , vol.130 , pp. 400-404
    • Wenzel, C.1    Hussian, D.2    Bartsch, R.3    Pluschnig, U.4    Locker, G.J.5    Rudas, M.6
  • 70
    • 33644683395 scopus 로고    scopus 로고
    • Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial
    • Coudert B.P., Arnould L., Moreau L., Chollet P., Weber B., Vanlemmens L., et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann. Oncol. 17 (2006) 409-414
    • (2006) Ann. Oncol. , vol.17 , pp. 409-414
    • Coudert, B.P.1    Arnould, L.2    Moreau, L.3    Chollet, P.4    Weber, B.5    Vanlemmens, L.6
  • 72
    • 21044436148 scopus 로고    scopus 로고
    • Incorporating trastuzumab into the neoadjuvant treatment of HER2 - Overexpressing breast cancer
    • Montemurro F., and Aglietta M. Incorporating trastuzumab into the neoadjuvant treatment of HER2 - Overexpressing breast cancer. Clin. Breast Cancer 6 (2005) 77-80
    • (2005) Clin. Breast Cancer , vol.6 , pp. 77-80
    • Montemurro, F.1    Aglietta, M.2
  • 73
    • 20544460650 scopus 로고    scopus 로고
    • Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
    • Buzdar A.U., Ibrahim N.K., Francis D., Booser D.J., Thomas E.S., Theriault R.L., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 23 (2005) 3676-3685
    • (2005) J. Clin. Oncol. , vol.23 , pp. 3676-3685
    • Buzdar, A.U.1    Ibrahim, N.K.2    Francis, D.3    Booser, D.J.4    Thomas, E.S.5    Theriault, R.L.6
  • 74
    • 33748543404 scopus 로고    scopus 로고
    • Prospective data of additional patients treated with neoadjuvant therapy with paclitaxel followed by FEC chemotherapy with trastuzumab in HER-2 positive operable breast cancer, and an update of initial study
    • (abs 5049)
    • Buzdar A.U., Valero V., Ibrahim N., Francis D., Theriault R., Green M., et al. Prospective data of additional patients treated with neoadjuvant therapy with paclitaxel followed by FEC chemotherapy with trastuzumab in HER-2 positive operable breast cancer, and an update of initial study. Breast Cancer Res. Treat. (2005) (abs 5049)
    • (2005) Breast Cancer Res. Treat.
    • Buzdar, A.U.1    Valero, V.2    Ibrahim, N.3    Francis, D.4    Theriault, R.5    Green, M.6
  • 75
    • 33847272860 scopus 로고    scopus 로고
    • N.L. Spector, K. Blackwell, J. Hurley, J.L. Harris, D. Lombandi, S. Bacus, et al., EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response. Proc. Am. Soc. Clin. Oncol. (2006) (abs 502).
  • 76
    • 19944408390 scopus 로고    scopus 로고
    • Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial
    • Polychronis A., Sinnett H.D., Hadjiminas D., Singhal H., Mansi J.L., Shivapatham D., et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol. (2005) 383-391
    • (2005) Lancet Oncol. , pp. 383-391
    • Polychronis, A.1    Sinnett, H.D.2    Hadjiminas, D.3    Singhal, H.4    Mansi, J.L.5    Shivapatham, D.6
  • 77
    • 33749642964 scopus 로고    scopus 로고
    • Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenopausal women with ER/PgR + breast cancer
    • (abs 515)
    • Dowsett M., Smith I., Skene A., Llombart A., Mayordomo J., Detre S., et al. Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenopausal women with ER/PgR + breast cancer. Proc. Am. Soc. Clin. Oncol. (2006) (abs 515)
    • (2006) Proc. Am. Soc. Clin. Oncol.
    • Dowsett, M.1    Smith, I.2    Skene, A.3    Llombart, A.4    Mayordomo, J.5    Detre, S.6
  • 78
    • 33847260883 scopus 로고    scopus 로고
    • Operable Breast Cancer: preliminary results of a phase II, double blind, placebo controlled, randomized trial of preoperative chemotherapy ± gefitinib with biomarkers evaluation
    • (abs 5048)
    • Guarneri V., Frassoldati A., Ficarra G., Giovannelli S., Borghi F., Puglisi F., et al. Operable Breast Cancer: preliminary results of a phase II, double blind, placebo controlled, randomized trial of preoperative chemotherapy ± gefitinib with biomarkers evaluation. Breast Cancer Res. and Treat. 94 (2005) s222 (abs 5048)
    • (2005) Breast Cancer Res. and Treat. , vol.94
    • Guarneri, V.1    Frassoldati, A.2    Ficarra, G.3    Giovannelli, S.4    Borghi, F.5    Puglisi, F.6
  • 79
    • 33644863001 scopus 로고    scopus 로고
    • Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
    • Wedam S.B., Low J.A., Yang S.X., Chow C.K., Choyke P., Danforth D., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 24 (2006) 769-777
    • (2006) J. Clin. Oncol. , vol.24 , pp. 769-777
    • Wedam, S.B.1    Low, J.A.2    Yang, S.X.3    Chow, C.K.4    Choyke, P.5    Danforth, D.6
  • 82
    • 2942729848 scopus 로고    scopus 로고
    • Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer
    • Ayers M., Symmans W.F., Stec J., Damokosh A.I., Clark E., Hess K., et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol. 22 (2004) 2284-2293
    • (2004) J. Clin. Oncol. , vol.22 , pp. 2284-2293
    • Ayers, M.1    Symmans, W.F.2    Stec, J.3    Damokosh, A.I.4    Clark, E.5    Hess, K.6
  • 83
    • 0042125511 scopus 로고    scopus 로고
    • Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer
    • Chang J.C., Wooten E.C., Tsimelzon A., Hilsenbeck S.G., Gutierrez M.C., Elledge R., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 (2003) 362-369
    • (2003) Lancet , vol.362 , pp. 362-369
    • Chang, J.C.1    Wooten, E.C.2    Tsimelzon, A.3    Hilsenbeck, S.G.4    Gutierrez, M.C.5    Elledge, R.6
  • 84
    • 20044390359 scopus 로고    scopus 로고
    • Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients
    • Chang J.C., Wooten E.C., Tsimelzon A., Hilsenbeck S.G., Gutierrez M.C., Tham Y.L., et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J. Clin. Oncol. 23 (2005) 1169-1177
    • (2005) J. Clin. Oncol. , vol.23 , pp. 1169-1177
    • Chang, J.C.1    Wooten, E.C.2    Tsimelzon, A.3    Hilsenbeck, S.G.4    Gutierrez, M.C.5    Tham, Y.L.6
  • 86
    • 33646339959 scopus 로고    scopus 로고
    • Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer
    • Thuerigen O., Schneeweiss A., Toedt G., Warnat P., Hahn M., Kramer H., et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J. Clin. Oncol. 24 (2006) 1839-1845
    • (2006) J. Clin. Oncol. , vol.24 , pp. 1839-1845
    • Thuerigen, O.1    Schneeweiss, A.2    Toedt, G.3    Warnat, P.4    Hahn, M.5    Kramer, H.6
  • 87
    • 28044472321 scopus 로고    scopus 로고
    • Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer
    • Gianni L., Zambetti M., Clark K., Baker J., Cronin M., Wu J., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 23 (2005) 7265-7277
    • (2005) J. Clin. Oncol. , vol.23 , pp. 7265-7277
    • Gianni, L.1    Zambetti, M.2    Clark, K.3    Baker, J.4    Cronin, M.5    Wu, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.